News -
Check out the posts below to learn the latest updates on our progress
- September 16 2022EXUMA Biotech to Present at the 2022 Cancer Immunology and Immunotherapy Conference and to Participate in the 7th Annual CAR-TCR SummitPR Newswire
- September 15 2022In vivo generation of tumor-metabolism-regulated HER2-specific CAR+ cells eradicate established HER2+ gastric carcinomas with the novel subcutaneous route of administration of CD3-directed lentivector-loaded lymphocytes.
- September 8 2022EXUMA Biotech to Participate in the Upcoming Baird Global Healthcare Investor ConferencePR Newswire
- June 18 2019EXUMA Biotechnology Expands Leadership Team with Appointment of Chief Medical Officer and Chief Financial OfficerPRNewswire
- May 21 2019Shanghai Perhum Therapeutics Announces Preliminary Results Of Two First-in-Human Solid Tumor CAR-T ProductsPRNewswire
- November 13 2018F1 Oncology’s International Affiliate, EXUMA Biotechnology, Announces Acquisition of Strategic CAR-T Assets
- January 6 2017BioAtla and F1 Oncology Announce Global Collaboration to Develop Adoptive Cellular Therapies for Solid Tumors